Effects of ACE inhibitors on insulin resistance and lipid profile in children with metabolic syndrome

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 5, Issue 3, 2013, Pages 164-169

  Çelebi Bitkin, Eda ^a   Boyraz, Mehmet ^b   Taşkin, Necati ^c   Akçay, Arzu ^c   Ulucan, Korkut ^d   Bedir Akyol, Mehmet ^e   Akçay, Teoman ^e  

^a Van High Specialty Education and Research Hospital   (Turkey)

^b FATIH UNIVERSITY   (Turkey)

^c Kanuni Sultan Suleyman Education and Research Hospital   (Turkey)

^d USKUDAR UNIVERSITY   (Turkey)

^e Education and Research Hospital   (Turkey)

Author keywords

ACE inhibitor; Insulin resistance; Metabolic syndrome

Indexed keywords

CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CHILD; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SCHOOL CHILD;

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; CHILD; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; OBESITY; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84884227901     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/Jcrpe.1020     Document Type: Article

References (26)

1. Han JC, Lawlor DA, Kimm SY. Chilhood and obesity. Lancet 2010;375:1737-1748.
2. Kelishadi R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev 2007;29:62-76. Epub 2007 May 3
3. Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care 2002;8(Suppl 11):283-292.
4. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998;338:1650-1656.
5. Cook S, Woitzman M, Auinger P, Nguyon M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1998-1994. Arch Pediatr Adolesc Med 2003;157:821-827.
6. Srinivasan S, Meyers, Berenson G. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: The Bogalusa Heart Study. Diabetes 2002;51:204-209.
7. Weiss R, Dziura J, Burget TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374.
8. Thamer M, Ray N, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999;21:1387-1400.
9. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995;345:1195-1198.
10. McMurray J, Fraser DM. Captopril, enalapril, and blood glucose. Lancet 1986;1:1035.
11. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P. Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 1990;89:811-813.
12. Morris AD, Boyle DI, McMahon AD, Pearce H, Evans JM, Newton RW, Jung RT, MacDonald TM. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 1997;20:1363-1367.
13. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873
14. Shimamoto K, Hirata A, Fukuoka M, Higashiura K, Miyazaki Y, Shiiki M, Masuda A, Nakagawa M, Iimura O. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994;23(Suppl 1):129-133.
15. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator activated receptor modulators with angiotensin receptor blocking activity. Diabetes 2005;54:3442-3452.
16. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006;47:1003-1009. Epub 2006 Mar 27
17. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J 2010;17:448-456.
18. Erbe DV, Gartrell K, Zhang Y, Suri V, Kirincich SJ, Will S, Perreault M, Wang S,Tobin JF. Molecular activation of PPAR gamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006;45:154-162. Epub 2006 May 16
19. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, doubleblind, placebo controlled 12-month study. Hypertens Res 2004;27:457-464.
20. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005;28:498.
21. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences. Diabetes Care 2005;28:757-758.
22. Nagel J, Tieetz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006;55:1149-1154.
23. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin resistant hypertension and cardiovascular disease. Diabetes Care 2004;27:1015.
24. Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens Suppl 1995;13:11-17.
25. Pepine CJ, Cooper-Dehoff RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 2004;44:509-512.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.